0001782223 2026-02-06 2026-02-06 true 0001782223 8-K/A 2026-02-06 Pyxis Oncology, Inc. DE 001-40881 83-1160910 321 Harrison Avenue Boston MA 02118 (617) 453-3596 false false false false Common Stock, par value $0.001 per share PYXS NASDAQ true true On February 6, 2026, Pyxis Oncology, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) announcing that, among other items, Lara Sullivan, M.D. ceased serving as the Chief Executive Officer, principal executive officer, and in any other executive capacity of the Company, effective February 2, 2026. This Amendment No. 1 to the Original Form 8-K is being filed to report a Separation and General Release Agreement (the “Separation Agreement”) between the Company and Dr. Sullivan.